Balyasny Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Balyasny Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-300,677	Closed	-$6.48M	–	2881
2025 Q4	$6.48M	Buy	+300,677	New	+$5.84M	0.01%	1260
2024 Q4	–	Sell	-166,263	Closed	-$2.18M	–	2716
2024 Q3	$2.18M	Sell	166,263 -118,036	-42%	-$1.8M	﹤0.01%	1631
2024 Q2	$4M	Sell	284,299 -25,413	-8%	-$414K	0.01%	1272
2024 Q1	$5.23M	Sell	309,712 -471,803	-60%	-$7.03M	0.01%	1201
2023 Q4	$11M	Buy	+781,515	New	+$9.18M	0.02%	823
2020 Q3	–	Sell	-97,687	Closed	-$789K	–	1276
2020 Q2	$789K	Buy	+97,687	New	+$861K	0.01%	866

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Balyasny Asset Management's AVDL Position: Q1 2026 in Review

Balyasny Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 300,677 shares — an estimated $6.48M sold.

Balyasny Asset Management first reported a position in AVDL in Q2 2020 and held it in 6 quarters. The position peaked at $11M in Q4 2023. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Balyasny Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Balyasny Asset Management sold 300,677 Avadel Pharmaceuticals shares in Q1 2026, an estimated $6.48M.
Balyasny Asset Management first reported a position in Avadel Pharmaceuticals in Q2 2020 and held it in 6 quarters.
Balyasny Asset Management's Avadel Pharmaceuticals position peaked at $11M in Q4 2023.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.